glp 1 late period GLP-1 receptor agonists and risk of suicide or suicide attempts – A nationwide cohort and self-controlled case series study Long-Term Weight Loss with GLP-1

August 20th, 2025: Federal Court Allows Most Ozempic and Wegovy Claims to Proceed in MDL A federal court has ruled that the majority of claims in the multidistrict litigation (MDL) against Eli Lilly and Novo Nordisk over their weight-loss drugs Ozempic and Wegovy will move forward

Aide repousser la fatigue durant l'activit physique (Cha et al

Patients who received semaglutide, however, reported more gastrointestinal adverse events (AEs)

What separates out that patient from the person who's coming in next, or you just saw, who has the same body mass index

However, regulatory uncertainties (pharma import tariffs, FDA scrutiny) mean many established biologics are still made in the US/EU companies favored sites ( [49] )

Although the Medicaid component of the BALANCE Model will launch May 1, the deadline for the state Medicaid agency Request for Applications (RFA) is July 31, 2026